NRC Health (NRC) 株式分析

企業概要

National Research Corporation is a specialized firm dedicated to delivering analytics and insights designed to measure and enhance the experience of both patients and employees within United States healthcare organizations. The company operates within the Healthcare sector, specifically focusing on the Health Information Services industry, where it leverages data to improve operational tracking regarding awareness, perception, and collaboration. As of the latest reporting period, the organization maintains a market capitalization of $387.60M and generates annual revenue of $137.39M while employing a workforce of 357 individuals. These valuation and revenue figures indicate that the company occupies a mid-cap position in the market, suggesting a scale significant enough to influence its niche but limited relative to large-cap healthcare information giants. The specific focus on subscription-based services for tracking organizational experience highlights a business model reliant on recurring revenue streams and deep integration with healthcare infrastructure.

財務健全性

The company reported a trailing twelve-month revenue of $137.39M, with net income of $11.29M and EBITDA reaching $37.00M, illustrating a distinct gap between top-line generation and bottom-line profitability. This disparity reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a substantial portion of revenue before arriving at net income, resulting in a net income figure that is less than one-third of the EBITDA. The entity generated free cash flow of $16.65M, which provides a measure of financial flexibility essential for covering debt obligations, capital expenditures, and working capital requirements without relying solely on external financing. While the company holds cash reserves of $4.14M, its total debt stands at $80.24M, creating a situation where liabilities significantly exceed liquid assets available for immediate deployment. The debt-to-equity ratio of 573.55 indicates a highly leveraged balance sheet, reflecting a capital structure heavily weighted towards debt financing rather than equity. Furthermore, the current ratio of 0.55 suggests that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity pressures. Return on equity stands at 51.2% while return on assets is 13.7%, metrics that reveal management's ability to generate substantial returns on shareholder capital despite the high leverage and specific asset base composition.

バリュエーション評価

The trailing P/E ratio is 34.08, whereas the forward P/E is 14.69, implying that the market expects a significant contraction in earnings per share or a substantial re-rating in the future to justify the current price levels. The price-to-book ratio of 27.57 indicates that the market is pricing the company at a substantial premium over its book value, reflecting high expectations for future growth or intangible asset value not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 2.82 and an EV/EBITDA of 12.53 suggest that the stock is valued relatively high compared to its sales base but appears more reasonable when normalized by earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range of $9.76 to $22.79, and given the current valuation context, the price sits below the recent highs, reflecting market caution regarding the earnings trajectory. With a beta of 0.41, the stock exhibits lower volatility relative to the broader market, indicating that its price movements are less sensitive to general market fluctuations. These metrics collectively present a valuation profile where earnings multiples are high historically but forward-looking multiples are significantly compressed.

Growth & Income

Revenue growth for the trailing twelve months was -4.6%, while earnings growth declined by -74.4%, indicating that earnings are shrinking at a rate far more aggressive than the revenue decline. This divergence implies that cost reductions or margin compression have not been sufficient to offset the drop in top-line revenue, leading to a severe contraction in profitability relative to sales. The company maintains a dividend yield of 3.2% with a payout ratio of 104.0%, meaning the company is distributing more in dividends than its current net income generates. This payout ratio is not sustainable given the negative earnings growth and suggests that the dividend may be at risk if earnings do not improve significantly in the near future. The overall growth and income profile is characterized by negative earnings momentum coupled with a high dividend yield that exceeds current earnings generation capabilities.